Project description
Clinical validation of natural product for the treatment of overactive bladder symptoms
Overactive bladder (OAB) syndrome, with urinary symptoms of urgency and nocturia, affects 500 million people worldwide, with prevalence increase with age (>30 % over 75 years old). Icelandic SagaNatura has developed NO-GO, a natural product from the leaves of Angelica archangelica for improving OAB symptoms as a non-prescription urinary product. Its efficiency and safety were recently clinically validated in a small-scale clinical trial on 66 patients with OAB. The current EU-funded NO-GO phase2 project aims to fine-tune the formulation, increase the production capacity and extend the clinical validation. The objective is to prepare the product for expansion in Europe and North American markets.
Fields of science
Programme(s)
Funding Scheme
SME-2 - SME instrument phase 2
Coordinator
221 Hafnarfjordur
Iceland
See on map